Observation of clinical effect of montelukast sodium in the treatment of chronic cough with small airway disease / 中国基层医药

ABSTRACT

Objective To explore the clinical efficacy of montelukast sodium in the treatment of chronic cough with small airway disease.Methods 50 chronic cough patients with small airway disease were selected,and they were randomly divided into montelukast sodium group and control group according to the digital table,25 cases in each group.The control group was given conventional treatment,the montelukast sodium group was treated with montelukast sodium on the basis of routine treatment.At the end of treatment,the clinical effect of the two groups was compared.Results The total effective rate of the montelukast sodium group was 92.0％,which of the control group was 84.0％,the difference was not statistically significant between the two groups (x2 =1.05,P ＞ 0.05).After 3 months of treatment,the pulmonary function of the two groups was significantly improved.Compared with the control group,the FEV1,FVC and FEV1/FVC％ of the montelukast sodium group showed no statistically significant differences(t =0.71,0.64,1.46,all P ＞ 0.05),but the FEF25 ％-75 ％,FEF50％,FEF75 ％ improved significantly with significant differences (t =7.07,2.62,3.83,all P ＜ 0.01).After 6 months of treatment,the difference of FEF75 ％ was statistically significant between the two groups (t =1.92,P ＜ 0.05).Compared with the control group,the level of serum IgE was significantlylower in the montelukast sodium group(t =4.02,P ＜0.01).There were no serious adverse reactions in the two groups,the difference was not statistically significant (x2 =1.42,P ＞ 0.05).Conclusion Montelukast sodium in the treatment of chronic cough with small airway disease has significant effcet,it is conducive to improve small airway disease and reduce serum IgE level,it is safe,effective and worthy of clinical application.